Pralmorelin Explained

Pralmorelin (INN) (brand name GHRP Kaken 100; former developmental code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by Kaken Pharmaceutical in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD).[1] [2] [3]

Pralmorelin is an orally-active, synthetic peptide drug, specifically, an analogue of met-enkephalin, with the amino acid sequence D-Ala-D-(β-naphthyl)-Ala-Trp-D-Phe-Lys-NH2.[4] It acts as a ghrelin/growth hormone secretagogue receptor (GHSR) agonist, and was the first of this class of drugs to be introduced clinically. Acute administration of the drug markedly increases the levels of plasma growth hormone (GH)[5] and reliably induces sensations of hunger and increases food intake in humans.[6]

Pralmorelin was also under investigation for the treatment of GHD and short stature (pituitary dwarfism), and made it to phase II clinical trials for these indications, but was ultimately never marketed for them. This may be because the ability of pralmorelin to increase plasma GH levels is significantly lower in people with GHD relative to healthy individuals.

See also

Notes and References

  1. Graul AI, Prous JR . The Year's New Drugs: A Historical and Research Perspective on the 41 New Products that Reached their First Markets in 2005. Drug News & Perspectives. 19. 1. 2006. 33. 0214-0934.
  2. Moulin A, Brunel L, Verdié P, Gavara L, Martinez J, Fehrentz JA . Ghrelin Receptor Ligands: Design and Synthesis of Pseudopeptides and Peptidomimetics. Current Chemical Biology. 7. 3. 2014. 254–270. 2212-7968. 10.2174/2212796807999131128125920.
  3. Book: Jameson JL, De Groot LJ . Endocrinology: Adult and Pediatric: Expert Consult - Online. 25 February 2015. Elsevier Health Sciences. 978-0-323-32195-2. 1366–.
  4. ((Adis Editorial)) . Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN . Drugs in R&D . 5 . 4 . 236–239 . 2004 . 15230633 . 10.2165/00126839-200405040-00011 .
  5. Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M . General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide . Arzneimittel-Forschung . 54 . 12 . 868–880 . 2004 . 15646371 . 10.1055/s-0031-1297042 . 28632234 .
  6. Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, D'Alessio D, Depoortere I, Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S, Dickson SL, Diéguez C, Granata R, Grill HJ, Grove K, Habegger KM, Heppner K, Heiman ML, Holsen L, Holst B, Inui A, Jansson JO, Kirchner H, Korbonits M, Laferrère B, LeRoux CW, Lopez M, Morin S, Nakazato M, Nass R, Perez-Tilve D, Pfluger PT, Schwartz TW, Seeley RJ, Sleeman M, Sun Y, Sussel L, Tong J, Thorner MO, van der Lely AJ, van der Ploeg LH, Zigman JM, Kojima M, Kangawa K, Smith RG, Horvath T, Tschöp MH . 6 . Ghrelin . Molecular Metabolism . 4 . 6 . 437–460 . June 2015 . 26042199 . 4443295 . 10.1016/j.molmet.2015.03.005 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pralmorelin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.